Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease
Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.
Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.
Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.